Homepage 5 IW

IMPACTING LIVES THROUGH COLLABORATIVE TRIALS

PATIENTS

Gain access to promising therapies by participating in trials that maximize learning, offering hope in the fight against rare and deadly diseases.

CLINICIANS & RESEARCH SITES

Contribute to innovative trials that prioritize patient care, focus on scientific precision, and enable quicker access to new, investigational treatments.

BIOTECH/PHARMACEUTICAL COMPANIES

Accelerate drug evaluation and approval by reducing time and cost while maintaining rigor with master protocols and adaptive trials that streamline the clinical trial process.

GCAR CLINICAL TRIALS
ADVANCING BREAKTHROUGHS FOR PATIENTS

GBM Agile Adaptive Global Innovative Learning Environment logo

GBM AGILE

Glioblastoma Adaptive Platform Trial Overview

Department of Defense M-PACT Logo

M-PACT

Military and Veterans PTSD Adaptive Platform Trial

REMAP-CAP Logo

REMAP-CAP/COVID

COVID-19 Adaptive Platform Trial

Ovarian Cancer RX Logo

OVARIAN CANCERX

Ovarian Cancer Adaptive Platform Trial

ARBOR BTC Logo

ARBOR BTC

Biliary Tract Cancer Master Protocol

Neurofibromatosis Platform Trial Logo

NEUROFIBROMATOSIS

Platform Trial

null

IMPACT PDAC

Pancreatic Ductal Adenocarcinoma Master Protocol

GCAR CLINICAL TRIALS
ADVANCING BREAKTHROUGHS FOR PATIENTS

null

GBM AGILE

Glioblastoma Adaptive Platform Trial Overview

null

M-PACT

Military and Veterans PTSD Adaptive Platform Trial

null

REMAP-CAP/COVID

COVID-19 Adaptive Platform Trial

null

OVARIAN CANCERX

Ovarian Cancer Adaptive Platform Trial

null

ARBOR BTC

Biliary Tract Cancer Master Protocol

null

NEUROFIBROMATOSIS

Platform Trial

null

IMPACT PDAC

Pancreatic Ductal Adenocarcinoma Master Protocol

INTERNATIONAL TRIAL SITES.
INDIVIDUAL ATTENTION.

78

Trial Sites

606

Scientific Investigators

29

Partners

2400

Patient Participants (through Q1 2024)

NEWS & PUBLICATIONS

STAY INFORMED ON GROUNDBREAKING RESEARCH

Join our newsletter to receive the latest updates on GCAR’s clinical trials, patient care advancements, and opportunities for collaboration.

Subscribe

* indicates required